BioSpace News Archive

Ocugen, Inc. today announced that upon recommendation from the U.S. Food and Drug Administration (FDA), it will pursue submission of a biologics license application (BLA) for its COVID-19 vaccine candidate, COVAXIN™.

- Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock - Proposals 1, 2, and 4 were approved at the Annual Meeting - Scheduled to Reconvene July 8, 2021, 9:00 a.m. Eastern Daylight Time.

Expands Global Access to Exceptional Quality Diagnostic-like CT Images for Medical Care Teams Using the Radixact System.

Targovax today announces mOS between 21.9 and 25.0 months from the randomized phase 1/2 trial of ONCOS-102 in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma (MPM).

HiberCell, today announced the initiation of a Phase 1a multicenter, open-label, dose escalation trial of its orally administered HC-5404-FU in patients with selected metastatic solid tumors. HC-5404-FU is an endoplasmic reticulum (ER) stress modulator, and the Investigational New Drug (IND) application received the greenlight from the U.S. Food and Drug Administration (FDA) in late 2020.

Cue Biopharma, Inc. (Nasdaq: CUE), announced today that it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of CUE-101 at the recommended Phase 2 dose of 4mg/kg.

Vor Biopharma (Nasdaq: VOR) and Abound Bio today announced they have entered into a multi-year strategic collaboration and license agreement to research both single- and multi-targeted CAR-T treatments to be used in combination with Vor’s engineered hematopoietic stem cell (eHSC) platform.

Veranome Biosystems LLC and Portal Bioscience LLC today announced the companies have entered into a co-development agreement to develop cutting-edge products that overcome the analytical challenges posed by the varying levels of RNA degradation often found in clinical specimens.

Ossianix, an antibody engineering company, and the University of Graz today announced the publication of a preclinical study that describes discovery of highly potent neutralizing single domain shark antibodies (VNARs) directed against the SARS-CoV-2 spike protein.

InterVenn Biosciences today announced it has completed clinical and analytical validation in compliance with standards set by the Clinical Laboratory Improvement Amendments (CLIA).